FrancophonIA/ELRC3.0 huggingface dataset:
English: The overall incidence and pattern of adverse reactions reported with MicardisPlus 80 mg/25 mg was comparable with MicardisPlus 80 mg/12.5 mg. A dose-relationship of adverse reactions was not established and they showed no correlation with gender, age or race of the patients.
Slovenian: Celokupno pogostnost in vzorec (pojavljanja) neželenih učinkov zdravila MicardisPlus 80 mg/25 mg so primerjali z zdravilom MicardisPlus 80 mg/12,5 mg.
English: Musculoskeletal, connective tissue and bone disorders Rare:
Slovenian: Bolezni mišično-skeletega sistema, vezivnega tkiva in kosti Neznana:
English: There is no clinical experience with MicardisPlus in patients with hepatic impairment.
Slovenian: Z zdravilom MicardisPlus pri bolnikih z zmanjšanim delovanjem jeter ni izkušenj.
English: - class Ia antiarrythmics (e.g. quinidine, hydroquinidine, disopyramide) - class III antiarrythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide) - some antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine,
Slovenian: Enako velja za jemanje z naslednjimi zdravili, ki lahko povzročijo torsades de pointes (med njimi tudi z nekaterimi antiaritmiki), ker je hipokaliemija predisponirajoči dejavnik za pojav torsades de pointes: antiaritmiki skupine Ia (npr. kinidin, hidrokinidin, dizopiramid), antiaritmiki skupine III (npr. amiodaron, sotalol, dofetilid, ibutilid), nekateri antipsihotiki: (npr. tioridazin, klorpromazin, levomepromazin, trifluorperazin, ciamemazin, sulpirid, sultoprid, amisulprid, tiaprid, pimozid, haloperidol, droperidol), drugo: (npr. bepridil, cisaprid, difemanil, eritromicin i.v., halofantrin, mizolastin, pentamidin, sparfloksacin, terfenadin, vinkamin i.v.
English: MicardisPlus 80 mg/25 mg tablets are yellow and white, oval-shaped, two-layer tablets engraved with the company logo and the code 'H9'.
Slovenian: Izgled zdravila MicardisPlus in vsebina pakiranja Tablete zdravila MicardisPlus 80 mg/25 mg so rumene in bele, ovalne, dvoslojne, z vtisnjenim znakom podjetja in kodno številko 'H9'.
English: MicardisPlus 80 mg/25 mg tablets telmisartan/hydrochlorothiazide
Slovenian: MicardisPlus 80 mg/25 mg tablete telmisartan/hidroklorotiazid
English: Exacerbation or activation of systemic lupus erythematosus Metabolism and nutrition disorders Uncommon: Rare:
Slovenian: poslabšanje ali aktiviranje sistemskega eritematoznega lupusa
English: Adverse reactions known to occur with each component given singly but which have not been seen in clinical trials may occur during treatment with MicardisPlus.
Slovenian: Dodatni podatki o posameznih sestavinah zdravila Neželeni učinki, o katerih so poročali za posamezni sestavini zdravila, se lahko pojavijo tudi pri zdravilu MicardisPlus, čeprav jih v kliničnih preskušanjih kombinacije niso zasledili.
English: There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system.
Slovenian: Pri bolnikih z obojestransko zožitvijo ledvične arterije ali arterije samo ene delujoče ledvice zdravljenje z zdravili, ki delujejo na renin-angiotenzin-aldosteronski sistem, poveča nevarnost hude hipotenzije in zmanjšanja delovanja ledvic.
English: Upper respiratory tract infection (e.g. sore throat, inflamed sinuses, common cold), urinary tract infections, deficiency in red blood cells (anaemia), high potassium levels, slow heart rate (bradycardia), kidney impairment including acute kidney failure, weakness, cough.
Slovenian: Občasni neželeni učinki (pojavijo se pri največ 1 od 100 bolnikov): okužba zgornjih dihal (npr.boleče žrelo, vnetje sinusov, prehlad), okužbe sečil, pomanjkanje rdečih krvničk (anemija), visoka raven kalija, počasen srčni utrip (bradikardija), ledvična okvara, tudi akutna ledvična odpoved; oslabelost, kašelj.
English: Low platelet count (thrombocytopenia), increase in certain white blood cells (eosinophilia), serious allergic reaction (e.g. hypersensitivity, anaphylactic reaction, drug rash), low blood sugar levels (in diabetic patients), upset stomach, eczema (a skin disorder), arthrosis, inflammation of the tendons, decreased haemoglobin (a blood protein), somnolence.
Slovenian: Redki neželeni učinki (pojavijo se pri največ 1 od 1.000 bolnikov): majhno število trombocitov (trombocitopenija), povečano število nekaterih belih krvničk (eozinofilija), resne alergijske reakcije (npr. preobčutljivost, anafilaktična reakcija, medikamentni izpuščaj), nizka raven krvnega sladkorja (pri bolnikih s sladkorno boleznijo), želodčne težave, ekcem (kožna bolezen), artroza, vnetje kit, znižana raven hemoglobina (krvne beljakovine), zaspanost.
English: NAME OF THE MEDICINAL PRODUCT MicardisPlus 80 mg/25 mg tablets telmisartan/hydrochlorothiazide
Slovenian: IME ZDRAVILA MicardisPlus 80 mg/25 mg tablete telmisartan/hidroklorotiazid
English: Thiazides should be discontinued before carrying out tests for parathyroid function.
Slovenian: Pred preiskavo delovanja obščitnice je treba tiazide ukiniti.
English: MicardisPlus should be taken in patients whose blood pressure is not adequately controlled by telmisartan alone.
Slovenian: Bolniki, pri katerih krvnega tlaka ne moremo ustrezno uravnati s samim telmisartanom, jemljejo zdravilo MicardisPlus.
English: MicardisPlus 80 mg/12.5 mg tablets
Slovenian: MicardisPlus 40 mg/12,5 mg tablete MicardisPlus 80 mg/12,5 mg tablete
English: Cholestyramine and colestipol resins
Slovenian: bradikardija somnolenca
English: NAME OF THE MEDICINAL PRODUCT MicardisPlus 80 mg/12.5 mg tablets telmisartan/hydrochlorothiazide
Slovenian: IME ZDRAVILA MicardisPlus 80 mg/12,5 mg tablete telmisartan/hidroklorotiazid
English: NAME OF THE MEDICINAL PRODUCT MicardisPlus 40 mg/12.5 mg tablets telmisartan/hydrochlorothiazide
Slovenian: IME ZDRAVILA MicardisPlus 40 mg /12,5 mg tablete telmisartan/hidroklorotiazid
English: Inflammation of the lung (bronchitis), activation or worsening of systemic lupus erythematosus (a disease where the body's immune system attacks the body, which causes joint pain, skin rashes and fever); sore throat, inflamed sinuses, feeling sad (depression), difficulty falling asleep (insomnia), impaired vision, difficulty breathing, abdominal pain, constipation, bloating (dyspepsia), feeling sick (vomiting), inflammation of the stomach (gastritis), abnormal liver function (Japanese patients are more likely to experience this side effect), redness of the skin (erythema), allergic reactions such as itching or rash, increased sweating, hives (urticaria), joint pain (arthralgia) and pain in extremities, muscle cramps, flu-like-illness, pain, low levels of sodium, increased levels of creatinine, hepatic enzymes or creatine phosphokinase in the blood.
Slovenian: Redki neželeni učinki (pojavijo se pri največ 1 od 1.000 bolnikov): pljučno vnetje (bronhitis), aktiviranje ali poslabšanje sistemskega eritematoznega lupusa (bolezni, pri kateri telo napade človekov lastni imunski sistem, kar povzroči bolečine v sklepih, kožni izpuščaj in vročino), angina, vnetje sinusov, občutek žalosti (depresija), težave z uspavanjem (nespečnost), motnje vida, težave z dihanjem, trebušna bolečina, zaprtje, spahovanje (dispepsija), slabo počutje (bruhanje), želodčno vnetje (gastritis), motnje vdelovanju jeter (pri japonskih bolnikih obstaja večja verjetnost pojavljanja tega neželenega učinka), rdečica na koži (eritem), alergijske reakcije, na primer srbenje ali izpuščaj; povečano znojenje, urtikarija, bolečine v sklepih (artralgija) in v okončinah, mišični krči, gripi podobna bolezen, bolečina, nizka raven natrija, zvišaneravni kreatinina, jetrnih encimov ali kreatin-fosfokinaze v krvi.
English: MicardisPlus 80 mg/12.5 mg tablets telmisartan/hydrochlorothiazide
Slovenian: MicardisPlus 80 mg/12,5 mg tablete telmisartan/hidroklorotiazid
English: Decreased blood potassium levels, anxiety fainting (syncope), sensation of tingling, pins and needles (paraesthesia), feeling of spinning (vertigo), fast heart beat (tachycardia), heart rhythm disorders, low blood pressure, a sudden fall in blood pressure when you stand up, shortness of breath (dyspnoea), diarrhoea, dry mouth, flatulence, back pain, muscle spasm, muscle pain, erectile dysfunction (inability to get or keep an erection), chest pain, increased blood uric acid levels.
Slovenian: Občasni neželeni učinki (pojavijo se pri največ 1 od 100 bolnikov): znižana raven kalija v krvi, tesnoba, omedlevanje (sinkopa), ščemenje, mravljinci (parestezija), vrtoglavica, hiter srčni utrip (tahikardija), motnje srčnega ritma, nizek krvni tlak, nenadno znižanje krvnega tlaka med vstajanjem, zasoplost (dispneja), driska, suha usta, napenjanje, bolečina v hrbtu, mišični krč, bolečina v mišicah, erektilna disfunkcija (nezmožnost erekcije ali vzdrževanja erekcije), bolečina v prsnem košu, povečana raven sečne kisline v krvi.
English: MicardisPlus 40 mg/12.5 mg tablets telmisartan/hydrochlorothiazide
Slovenian: MicardisPlus 40 mg/12,5 mg tablete telmisartan/hidroklorotiazid
English: Telmisartan:
Slovenian: EXP:
English: MicardisPlus is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed.
Slovenian: Zdravila MicardisPlus ne priporočajo materam, ki dojijo.
English: Red ferric oxide (E172) Sodium hydroxide Sodium starch glycollate (type A) Sorbitol (E420).
Slovenian: 6.1 Seznam pomožnih snovi laktoza monohidrat magnezijev stearat koruzni škrob meglumin mikrokristalna celuloza povidon (K25) rdeč železov oksid (E172) natrijev hidroksid natrijev karboskimetilškrob (vrsta A) sorbitol (E420)
English: Yellow ferric oxide (E172) Sodium hydroxide Sodium starch glycollate (type A) Sorbitol (E420).
Slovenian: 6.1 Seznam pomožnih snovi laktoza monohidrat magnezijev stearat koruzni škrob meglumin mikrokristalna celuloza povidon (K25) rumen železov oksid (E172) natrijev hidroksid natrijev karboskimetilškrob (vrsta A) sorbitol (E420)
English: Although clinically significant hyperkalaemia has not been documented with MicardisPlus, risk factors for the development of hyperkalaemia include renal insufficiency and/or heart failure, and diabetes mellitus.
Slovenian: Dejavniki tveganja za njen razvoj so zmanjšano delovanje ledvic ali srčno popuščanje ali obe obolenji in diabetes mellitus.
English: It may harm them,
Slovenian: ki so prejemali emtricitabin,
English: • changes to your urine.
Slovenian: • spremembe urina.
English: Date of first authorisation: 9 November 2016
Slovenian: DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 9. november 2016
English: • Reminders for evaluations/counselling at the initial visit and follow-up.
Slovenian: • opozorila na oceno/svetovanje pri prvem obisku in v fazi spremljanja.
English: Keep the tablet bottle with you so that you can easily describe what you have taken.
Slovenian: S seboj imejte plastenko tablet, da boste lahko opisali, kaj ste zaužili
English: • swelling of the face, lips, tongue or throat,
Slovenian: • oteklost obraza, ustnic, jezika ali grla,
English: Tell your doctor if you are taking any of these medicines.
Slovenian: Obvestite zdravnika, če jemljete katero koli od teh zdravil.
English: • Many HIV tests can miss a recent infection.
Slovenian: • Mnogi diagnostični testi za HIV lahko spregledajo nedavno okužbo.
English: • increased creatine kinase.
Slovenian: • povišanje kreatin-kinaze.
English: EU/1/16/1148/001 EU/1/16/1148/002
Slovenian: EU/1/16/1148/002
English: Importance of adherence
Slovenian: Pomembnost adherence
English: • difficulty sleeping, abnormal dreams,
Slovenian: • težave s spanjem, nenavadne sanje,
English: Then mix the powder with about 100 ml (half a glass) of water, orange juice or grape juice, and drink immediately.
Slovenian: Nato zmešajte prašek s približno 100 ml (pol kozarca) vode, pomarančnega ali grozdnega soka in nemudoma popijte.
English: Rare hepatic steatosis, hepatitis
Slovenian: Redko hepatična steatoza, hepatitis
English: If this applies to you, tell your doctor immediately.
Slovenian: Če to velja za vas, o tem nemudoma obvestite zdravnika.
English: If you notice these or any symptoms of inflammation or infection, get medical help immediately.
Slovenian: Če opazite te ali kakršne koli druge simptome vnetja ali okužbe, nemudoma poiščite zdravniško pomoč.
English: EU/1/16/1148/001 30 film-coated tablets EU/1/16/1148/002 90 (3x30) film-coated tablets
Slovenian: EU/1/16/1148/001 30 filmsko obloženih tablet EU/1/16/1148/002 90 (3x30) filmsko obloženih tablet
English: • Adults: one tablet each day, where possible, with food.
Slovenian: • Odrasli: ena tableta vsak dan s hrano, če je mogoče.
English: • Additional risk minimisation measures
Slovenian: • Dodatni ukrepi za obvladovanje tveganja
English: Up to 30% of the emtricitabine dose and approximately 10% of the tenofovir dose can be removed by haemodialysis.
Slovenian: Do 30% odmerka emtricitabina in približno 10% odmerka tenofovirja se lahko odstrani s hemodializo.
English: Excipient with known effect: each tablet contains a maximum of 9.53 mg sodium.
Slovenian: Pomožna snov z znanim učinkom: ena tableta vsebuje največ 9,53 mg natrija.
English: • Lactic acidosis (excess lactic acid in the blood) is a rare but potentially life-threatening side effect.
Slovenian: • laktacidoza (preveč mlečne kisline v krvi) je redek, a potencialno življenjsko nevaren neželeni učinek.
English: Resistance in vitro
Slovenian: Rezistenca in vitro
English: If you think you may have lactic acidosis, get medical help immediately.
Slovenian: Če menite, da bi lahko imeli laktacidozo, nemudoma poiščite zdravniško pomoč.
English: ANNEX II A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Slovenian: A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO
English: • interleukin-2 (to treat cancer).
Slovenian: • interlevkin-2 (za zdravljenje raka)
English: The potential risks and benefits associated with co-administration should be considered, particularly in patients at increased risk of renal dysfunction.
Slovenian: Upoštevati je treba možna tveganja in koristi, povezane s sočasnim dajanjem, še posebej pri bolnikih s povečanim tveganjem za ledvično odpoved.
English: • feeling weak.
Slovenian: • občutek oslabelosti.
English: Contents of the pack:
Slovenian: Vsebina pakiranja:
English: • low white blood cell count (a reduced white blood cell count can make you more prone to infection),
Slovenian: • nizko število belih krvnih telesc (zmanjšanje števila belih krvnih telesc lahko povzroči večjo nagnjenost k okužbam),
English: Renal clearance has been estimated to be approximately 210 ml/min, which is in excess of the glomerular filtration rate.
Slovenian: Ocenjeno je, da znaša ledvični očistek približno 210 ml/min, kar presega nivo glomerularne filtracije.
English: Rare osteomalacia (manifested as bone pain and infrequently contributing to fractures)1,3, myopathy1
Slovenian: Redko osteomalacija (ki se kaže kot bolečine v kosteh in redko prispeva k zlomom)1,3, miopatija1
English: HIV-Positive Subjects
Slovenian: HIV-pozitivne osebe
English: • Get tested for other sexually transmitted infections such as syphilis and gonorrhoea.
Slovenian: Testirajte se za druge spolno prenosljive okužbe, kot sta sifilis in gonoreja.
English: Due to limitations of the study, a benefit of tenofovir disoproxil over placebo was not demonstrated based on plasma HIV-1 RNA levels at week 24.
Slovenian: Zaradi omejitev študije korist dizoproksiltenofovirata glede na placebo ni bila dokazana na podlagi plazemskih ravni HIV-1 RNA v 24. tednu.
English: • Lactic acidosis (see Possible serious side effects)
Slovenian: • laktična acidoza (glejte Možni resni neželeni učinki),
English: TLOVR = Time to Loss of Virologic Response a Van Elteren Test
Slovenian: TLOVR = Time to Loss of Virologic Response (čas do izgube virološkega odziva) a Van Elternov test
English: Eight of the 89 patients (9.0%) discontinued study drug due to renal adverse events.
Slovenian: Osem od 89 bolnikov (9,0 %) je zdravljenje s študijskim zdravilom prekinilo zaradi ledvičnih neželenih dogodkov.
English: ** The p-value based on the Cochran-Mantel-Haenszel Test stratified for baseline CD4 cell count.
Slovenian: ** Vrednost p temelji na Cochran-Mantel-Haenszlovem testu, stratificiranem za število celic CD4 ob izhodišču.
English: • anaemia (low red blood cell count),
Slovenian: • anemija (nizko število rdečih krvnih telesc),
English: Age (Yrs), Median (Q1, Q3) Gender, N (%)
Slovenian: Starost (leta), mediana (Q1, Q3) Spol, N (%)
English: • increased triglycerides (fatty acids), bile or sugar in the blood,
Slovenian: • povišani trigliceridi (maščobne kisline), bilirubin (žolčno barvilo) ali sladkor v krvi,
English: b Relative risk reduction calculated for mITT based on incident seroconversion, ie, occurring post-baseline through first post-treatment visit (approximately 1 month after last study drug dispensation).
Slovenian: b Relativno zmanjšanje tveganja, izračunano za mITT na podlagi dogodka serokonverzije, tj. pojav po izhodišču do prvega obiska po zdravljenju (približno 1 mesec po zadnjem odmerku preiskovanega zdravila).
English: A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no malformations or foetal/neonatal toxicity associated with emtricitabine and tenofovir disoproxil.
Slovenian: Veliko število podatkov pri nosečnicah (več kot 1.000 izpostavljenih nosečnosti) ne kaže na malformacije ali feto/neonatalno toksičnost, povezane z emtricitabinom in dizoproksiltenofoviratom.
English: • non-steroidal anti-inflammatory drugs (NSAIDs, to relieve bone or muscle pains).
Slovenian: • nesteroidna protivnetna zdravila (NSAID, za lajšanje bolečin v kosteh ali mišicah)
English: Tenofovir is primarily excreted by the kidney by both filtration and an active tubular transport system with approximately 70 - 80% of the dose excreted unchanged in urine following intravenous administration.
Slovenian: Tenofovir se primarno izloča preko ledvic tako s filtracijo kot z aktivnim tubularnim transportnim sistemom, pri čemer se po intravenskem vnosu približno 70-80% odmerka izloči nespremenjenega z urinom.
English: • softening of the bones (with bone pain and sometimes resulting in fractures).
Slovenian: • mehčanje kosti (z bolečinami v kosteh, včasih tudi zlom),
English: • this may cause the child to be tired or breathless
Slovenian: To lahko povzroči utrujenost ali zasoplost otroka.
English: • breakdown of muscle, muscle pain or weakness which may occur due to damage to the kidney tubule cells.
Slovenian: • razpad mišičnega tkiva, bolečine v mišicah ali mišična oslabelost, ki se lahko pojavi zaradi poškodovanja celic ledvičnih tubulov.
English: • Do not share or re-use needles or other injection or drug equipment.
Slovenian: Ne delite ali ponovno uporabljajte igel ali drugih pripomočkov za injiciranje in za ostale oblike jemanja drog.
English: • Do not share personal items that can have blood or body fluids on them, such as toothbrushes and razor blades.
Slovenian: Ne delite osebnih predmetov, na katerih so lahko kri ali telesne tekočine, kot so zobne ščetke in brivniki.
English: The primary efficacy endpoint for this study was the achievement and maintenance of confirmed HIV-1 RNA concentrations < 400 copies/ml over 48 weeks.
Slovenian: Primarni cilj učinkovitosti pri tej študiji je bilo doseganje in vzdrževanje potrjenih koncentracij HIV-1 RNA < 400 kopij/ml v 48 tednih.
English: Taking Emtricitabine/Tenofovir disoproxil Zentiva with other medicines that can damage your kidneys: it is especially important to tell your doctor if you are taking any of these medicines, including
Slovenian: Jemanje zdravila Emtricitabin/dizoproksiltenofovirat Zentiva z drugimi zdravili, ki lahko poškodujejo vaše ledvice: posebno pomembno je, da svojega zdravnika obvestite, če jemljete katero od sledečih zdravil:
English: Emtricitabine/tenofovir disoproxil should only be used in individuals with creatinine clearance (CrCl) <80 ml/min if the potential benefits are considered to outweigh the potential risks.
Slovenian: Emtricitabin/dizoproksiltenofovirat se sme uporabljati samo pri posameznikih z očistkom kreatinina (CrCl) < 80 ml/min, če se oceni, da morebitne koristi odtehtajo morebitna tveganja.
English: Number with Tenofovir Detected/Total Samples (%)
Slovenian: Število zaznanih primerov tenofovirja/skupno vzorci (%)
English: 3 Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in HCV
Slovenian: 3 Študijo so izvedli z dodatnim voksilaprevirjem 100 mg za doseganje izpostavljenosti voksilaprevirju, ki se pričakuje pri bolnikih z okužbo s HCV.
English: Rare angioedema
Slovenian: Redko angioedem
English: Rare renal failure (acute and chronic), acute tubular necrosis, nephritis (including acute interstitial nephritis)3, nephrogenic diabetes insipidus
Slovenian: Redko ledvična odpoved (akutna in kronična), akutna tubularna nekroza, nefritis (vključno z akutnim intersticijskim nefritisom)3, nefrogeni insipidusni diabetes
English: This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodiumfree'.
Slovenian: Pomožne snovi To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na tableto, kar v bistvu pomeni ‘brez natrija'.
English: In infants and children older than 4 months, the majority of patients taking emtricitabine achieved or maintained complete suppression of plasma HIV-1 RNA through 48 weeks (89% achieved ≤ 400 copies/ml and 77% achieved ≤ 50 copies/mL).
Slovenian: Pri dojenčkih in otrocih, starejših od 4 mesece, je večina bolnikov, ki je jemala emtricitabin, dosegla ali ohranila popolno supresijo plazemske HIV-1 RNA do konca 48. tedna (89 % je doseglo ≤ 400 kopij/ml in 77 % je doseglo ≤ 50 kopij/ml).
English: • other allergic reactions, such as wheezing, swelling or feeling light-headed.
Slovenian: • druge alergijske reakcije, kot so piskanje, otekanje ali omotičnost.
English: Limited data from clinical studies support once daily dosing in HIV-1 uninfected individuals with CrCl 60-80 ml/min.
Slovenian: Omejeno število podatkov iz kliničnih študij podpira odmerjanje enkrat dnevno pri posameznikih, ki niso okuženi s HIV-1, s CrCl 60-80 ml/min.
English: If you have taken Emtricitabine/Tenofovir disoproxil Zentiva during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child.
Slovenian: Če ste zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva jemali med nosečnostjo, vas lahko zdravnik naroči na redne preiskave krvi in druge diagnostične preiskave, da bo spremljal razvoj vašega otroka.
English: The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3'-sulphoxide diastereomers (approximately 9% of dose) and conjugation with glucuronic acid to form 2'-O-glucuronide (approximately 4% of dose).
Slovenian: Biotransformacija emtricitabina vključuje oksidacijo tiolnega dela molekule, pri čemer nastanejo 3'-sulfoksid diastereomere (približno 9% odmerka) in konjugacijo z glukuronsko kislino, pri čemer nastane 2'-O-glukuronid (približno 4% odmerka).
English: • Reminder of factors to help identify individuals at high risk of acquiring HIV-1
Slovenian: • opozorilo na dejavnike, ki pomagajo določiti posameznike z visokim tveganjem za HIV-1;
English: The apparent clearance of tenofovir averaged approximately 307 ml/min.
Slovenian: Navidezni očistek tenofovirja je povprečno znašal približno 307 ml/min.
English: • Children given emtricitabine very commonly experienced changes in skin colour including
Slovenian: • Otroci, ki so dobivali emtricitabin, so imeli zelo pogosto spremembe obarvanosti kože vključno s temno obarvanimi kožnimi lisami.